Zacks Research Expects Reduced Earnings for Cardiff Oncology

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at Zacks Research cut their FY2027 earnings per share estimates for Cardiff Oncology in a research report issued to clients and investors on Monday, June 22nd. Zacks Research analyst J. Vandermosten now expects that the company will earn ($0.80) per share for the year, down from their prior forecast of ($0.76). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.66) per share. Zacks Research also issued estimates for Cardiff Oncology’s FY2028 earnings at ($0.79) EPS.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%.

CRDF has been the subject of a number of other reports. Piper Sandler reduced their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. HC Wainwright lowered shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a report on Monday, June 1st. TD Cowen cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Craig Hallum cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research report on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Monday, May 18th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.80.

Cardiff Oncology Trading Down 3.1%

CRDF opened at $1.26 on Wednesday. The company’s fifty day moving average price is $1.61 and its two-hundred day moving average price is $1.96. Cardiff Oncology has a 1-year low of $1.16 and a 1-year high of $4.55. The company has a market cap of $86.15 million, a price-to-earnings ratio of -1.88 and a beta of 1.36.

Insiders Place Their Bets

In other news, Director Gary W. Pace acquired 30,000 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were purchased at an average cost of $1.22 per share, with a total value of $36,600.00. Following the acquisition, the director directly owned 1,356,376 shares of the company’s stock, valued at $1,654,778.72. The trade was a 2.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mani Mohindru bought 24,703 shares of Cardiff Oncology stock in a transaction dated Thursday, June 18th. The stock was purchased at an average price of $1.21 per share, with a total value of $29,890.63. Following the purchase, the chief executive officer owned 24,703 shares in the company, valued at approximately $29,890.63. This represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in shares of Cardiff Oncology during the 1st quarter worth approximately $164,000. Sei Investments Co. bought a new position in shares of Cardiff Oncology in the first quarter valued at approximately $89,000. Raymond James Financial Inc. grew its holdings in shares of Cardiff Oncology by 70.1% in the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after acquiring an additional 9,740 shares in the last quarter. Brooklyn Investment Group purchased a new stake in shares of Cardiff Oncology during the third quarter valued at approximately $26,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Cardiff Oncology during the second quarter valued at approximately $43,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.